A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data

#747

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.

Aim(s): To evaluate the effectiveness of pasireotide long-acting release (LAR) in MTC pts with progressive disease.

Materials and methods: Trial enrollment started in February 2012 (study registration no. NCT01625520). Twenty pts are expected to be enrolled. At present, 11 consecutive pts with progressive metastatic or persistent postoperative MTC have been enrolled and received pasireotide LAR 60 mg/m.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,

A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data

#586

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.

Aim(s): To evaluate the effectiveness of pasireotide LAR in MTC patients with progressive disease.

Materials and methods: Patients with progressive metastatic MTC and evidence of biochemical progression are treated with pasireotide LAR 60 mg/month.

Conference:

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: Pasireotide, medullary thyroid cancer,